SIRT1 and Obesity: (2) There is an urgent need for large-scale clinical trials to ascertain the therapeutic efficacy and safety of SIRT1 modulators in patients with PAH, particularly in advanced disease stages, as these outcomes may be significantly influenced by sex and the presence of obesity, including long-term investigations.